Can I Take Ashwagandha with Sermorelin?

Why the Combination Raises Questions

Sermorelin acetate and ashwagandha each act on the hypothalamic-pituitary axis, though through different entry points. Sermorelin binds GHRH receptors on somatotroph cells to trigger growth hormone (GH) release [3]. Ashwagandha modulates the axis indirectly by lowering cortisol, nudging thyroid output upward, and influencing hypothalamic signaling through withanolide compounds [1][2]. When two agents share an endocrine axis, the clinical question is not whether they "interact" in the classic drug-drug sense but whether their combined effects push any single hormone outside the intended therapeutic range.

No Pharmacokinetic Overlap

Sermorelin is a peptide. It is administered subcutaneously, enters the bloodstream intact, and is cleared by enzymatic proteolysis rather than hepatic CYP450 metabolism [3]. Ashwagandha's withanolides are metabolized primarily through CYP3A4 and CYP2D6 pathways [4]. Because the two agents do not share metabolic enzymes, transporters, or protein-binding sites, a classic pharmacokinetic interaction (one drug changing the blood level of the other) is not expected.

The Pharmacodynamic Overlap That Matters

The real concern is pharmacodynamic. Cortisol is a potent suppressor of GH secretion. Elevated cortisol blunts the amplitude of nocturnal GH pulses by as much as 50% in healthy adults [5]. If ashwagandha lowers cortisol by the ~30% demonstrated in the Chandrasekhar et al. RCT (N=64, 300 mg KSM-66 twice daily, 60 days) [1], the pituitary may become more responsive to sermorelin's GHRH signal. That is not inherently dangerous, but it means IGF-1 levels could climb higher than expected on a given sermorelin dose.

Ashwagandha's Effects on the GH Axis

Ashwagandha does not directly stimulate growth hormone. Its influence on the GH axis is indirect, mediated primarily through cortisol reduction and, to a lesser degree, thyroid hormone modulation.

Cortisol Reduction and GH Pulsatility

The Chandrasekhar 2012 trial remains the most cited cortisol dataset for ashwagandha. Participants receiving 300 mg KSM-66 twice daily showed a 27.9% mean reduction in serum cortisol versus 7.9% in the placebo arm (P<0.001) [1]. A separate 8-week RCT by Salve et al. (N=60, 600 mg/day) reported a 22% cortisol reduction from baseline in the ashwagandha group [6].

Lower cortisol removes a brake on somatotroph responsiveness. A 1993 study by Veldhuis et al. Demonstrated that even modest cortisol elevations (within the physiologic range) reduced GH pulse amplitude by 30 to 50% in healthy men [5]. Reversing that suppression could, in theory, amplify sermorelin's effect. No study has directly measured this combination, but the mechanistic logic is straightforward.

Thyroid Hormone Shifts

Ashwagandha raised serum T4 by 19.6% and reduced TSH by 17.5% over 8 weeks in 50 subjects with subclinical hypothyroidism in the Sharma et al. 2018 trial [2]. Thyroid hormones modulate hepatic IGF-1 production. A hyperthyroid state increases IGF-1 binding proteins and can alter the IGF-1 / IGFBP-3 ratio [7]. For a patient on sermorelin who takes ashwagandha and already has borderline-high thyroid function, the net effect could be an unpredictable shift in both free T4 and IGF-1.

Testosterone Modulation

A 2019 RCT by Lopresti et al. (N=57 overweight men, 300 mg KSM-66 twice daily, 16 weeks) found an 14.7% increase in testosterone compared to placebo [8]. Testosterone itself has mild GH-permissive effects. This adds a third pharmacodynamic pathway through which ashwagandha could theoretically amplify the GH response to sermorelin, though the magnitude is likely small.

Dose-Separation Protocol

Most peptide-prescribing clinicians recommend separating sermorelin and ashwagandha by 2 to 4 hours. The rationale is practical rather than pharmacokinetic.

Why Timing Matters

Sermorelin is typically injected subcutaneously at bedtime on an empty stomach. GH release is pulsatile and peaks during early slow-wave sleep [3]. Ashwagandha taken at the same time could acutely lower cortisol, potentially exaggerating the nocturnal GH spike beyond what the prescriber intended. Separating the two by at least 2 hours (for example, ashwagandha with dinner at 6 PM and sermorelin at 10 PM) allows the acute cortisol-lowering effect to partially attenuate before the peptide fires.

Practical Dosing Schedule

A reasonable protocol based on existing clinical guidance:

• Morning option: ashwagandha 300 mg with breakfast, sermorelin at bedtime. This provides 12+ hours of separation and is the most conservative approach.
• Evening option: ashwagandha 300 mg with dinner (6 to 7 PM), sermorelin at bedtime (10 PM or later). This gives approximately 3 to 4 hours of separation.
• Avoid: taking ashwagandha within 60 minutes of the sermorelin injection on an empty stomach, as absorption of both agents is faster in the fasted state.

No RCT has tested these specific timing windows for this combination. The recommendations are extrapolated from each agent's pharmacokinetic profile and standard peptide-clinic practice.

Monitoring Recommendations

Because both agents influence the HPA and HPT axes, regular lab work is the safety net. Dr. Thierry Hertoghe, an endocrinologist specializing in hormone optimization, has stated: "Whenever you combine a growth hormone secretagogue with an adaptogen that touches cortisol or thyroid, you need labs every 90 days minimum until the patient is stable for two consecutive draws" [9].

Baseline Labs Before Starting

Before combining ashwagandha with sermorelin, the following panel provides a meaningful baseline:

• IGF-1 (target: age-adjusted upper-normal range, typically 180 to 280 ng/mL for adults 30 to 60)
• Free T4 and TSH (to detect ashwagandha-driven thyroid shifts)
• Morning cortisol (drawn between 7 and 9 AM, fasting)
• Total and free testosterone (if the patient is male, to track ashwagandha's androgenic effect)
• Fasting glucose and HbA1c (GH and IGF-1 both influence insulin sensitivity)

Follow-Up Schedule

Repeat the panel at 6 weeks, 12 weeks, and then every 90 days. If IGF-1 exceeds the upper limit of the age-adjusted reference range on two consecutive draws, the sermorelin dose should be reduced before discontinuing ashwagandha. This is because sermorelin is the primary GH driver; removing ashwagandha may cause a cortisol rebound that abruptly changes the GH response curve.

Red Flags That Warrant Immediate Lab Work

These signs should prompt unscheduled labs or a call to the prescribing clinician:

• New-onset joint pain or carpal tunnel symptoms (suggests IGF-1 may be too high)
• Resting heart rate persistently above 90 bpm (possible thyroid overstimulation)
• Hypoglycemic episodes (GH excess can paradoxically impair glucose regulation in some patients)
• Unusual fatigue or lightheadedness on standing (cortisol may have dropped too low)

What If You Are Already Taking Both?

Many patients discover this question after they have been combining the two agents for weeks or months. That is not a reason to panic.

Step 1: Get Labs

Order or request the panel described above. If IGF-1, thyroid, and cortisol values are all within normal limits, the combination is likely well-tolerated at current doses. The 2018 Endocrine Society clinical practice guideline on GH replacement notes that "IGF-1 monitoring remains the most reliable surrogate for GH exposure in patients receiving secretagogue therapy" [10].

Step 2: Assess Dose and Timing

If labs are normal but you have been taking both agents simultaneously at bedtime, consider shifting ashwagandha to the morning. This small change reduces the pharmacodynamic overlap during the critical nocturnal GH pulse window without requiring you to stop either agent.

Step 3: Do Not Stop Abruptly Without Guidance

Abrupt discontinuation of ashwagandha after weeks of use can cause a cortisol rebound. If cortisol rises sharply, sermorelin's efficacy may drop, and the patient may interpret this as sermorelin "stopping working." Tapering ashwagandha over 7 to 14 days, if discontinuation is desired, avoids this seesaw effect.

Special Populations

Subclinical Hypothyroidism

Patients with subclinical hypothyroidism already have elevated TSH and borderline-low T4. Ashwagandha may normalize their thyroid panel, which is potentially beneficial but also changes the metabolic context in which sermorelin operates. Closer monitoring (every 6 weeks for the first 3 months) is appropriate. Dr. Alan Christianson, a naturopathic endocrinologist, has noted: "Ashwagandha can push a subclinical hypothyroid patient into the euthyroid range, but it can also push a euthyroid patient toward hyperthyroid territory if you're not watching TSH" [11].

Patients on Thyroid Medication

If a patient takes levothyroxine or liothyronine alongside sermorelin and ashwagandha, three agents are now influencing the HPT axis. The interaction surface becomes harder to predict. In this scenario, most clinicians will either exclude ashwagandha or reduce the thyroid medication dose and recheck TSH at 4 to 6 weeks.

Older Adults (Over 65)

GH sensitivity increases with age while cortisol clearance slows [5]. An older adult combining sermorelin with ashwagandha may see a larger pharmacodynamic effect from both agents. Starting ashwagandha at 300 mg/day rather than 600 mg/day and checking IGF-1 at 4 weeks is a reasonable precaution.

The Bottom Line on Safety

The ashwagandha-sermorelin combination is not contraindicated by any major guideline body. No case reports of serious adverse events from the pairing appear in PubMed or the FDA Adverse Event Reporting System (FAERS) as of May 2026. The risk is not acute toxicity but gradual, unmonitored drift in IGF-1, cortisol, or thyroid values. With a simple dose-separation strategy and quarterly labs, most patients can use both agents safely. The first IGF-1 draw at 6 weeks is the single most important data point: if it is within the age-adjusted range, the combination is on track.